In recognition of World Diabetes Day, Adalvo highlights its diabetes portfolio, built with a focus on rapid market access and a strong IP strategy.
Our diabetes basket spans a wide range of treatments—from small molecules to peptide-based therapies, covering both oral solids and injectable options, with short- and long-acting formulations.
Highlights include a comprehensive Semaglutide selection, with treatments for diabetes (generic to Ozempic 2mg dose) and weight management (generic to Wegovy). Our Semaglutide for diabetes (generic to Ozempic) is already under registration in multiple countries, with plans for EU submission upon data exclusivity expiry.
Adalvo has also made significant progress with its DCP filings: Linagliptin and Empagliflozin+Metformin are under registration, and Dapagliflozin (5mg and 10mg) and Empagliflozin tablets (10mg and 25mg) have been approved.
Through strategic IP considerations, Adalvo enables its partners to achieve first-to-market success in the rapidly growing diabetes market, valued at $85 billion by IQVIA with an expected 30% 3Y CAGR.
At Adalvo, there are no half-measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Partner up now!